Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV
- Conditions
- HIV-1-infection
- Interventions
- Registration Number
- NCT04143594
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objective of this study is to evaluate the efficacy of lenacapavir (formerly GS-6207) containing regimens in people living with human immunodeficiency virus (HIV) (PLWH).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 183
- Antiretroviral (ARV) naive with no use of any ARV within one month of screening. Use of pre-exposure prophylaxis (PrEP) (any duration), post-exposure prophylaxis (PEP) (any duration), or HIV-1 treatment (< 10 days therapy total) > 1 month prior to screening is permitted
- HIV-1 ribonucleic acid (RNA) ≥ 200 copies/mL at screening
- Cluster Determinant 4+ (CD4+) cell count ≥ 200 cells/microliter at screening
Key
- Current Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Lenacapavir, F/TAF, and TAF Subcutaneous Lenacapavir Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and BIC Oral Lenacapavir Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and TAF Oral Lenacapavir Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and TAF F/TAF Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and TAF TAF Induction phase: Participants will receive lenacapavir (LEN) 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus emtricitabine/ tenofovir alafenamide (F/TAF) (200/25 mg) fixed-dose combination (FDC) tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via subcutaneous (SC) injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus TAF 25 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily TAF 25 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and BIC F/TAF Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and BIC Subcutaneous Lenacapavir Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. Lenacapavir, F/TAF, and BIC BIC Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. Lenacapavir and F/TAF Oral Lenacapavir Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. Lenacapavir and F/TAF F/TAF Induction phase: Participants will receive LEN 600 mg (2 X 300 mg, tablet) orally on Days 1 and 2, followed by LEN 300 mg tablet orally on Day 8 plus F/TAF (200/25 mg) FDC tablets once daily orally from Day 1 to Week 28 plus LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Day 15. Maintenance phase: Participants will receive LEN 927 mg (309 mg/mL; 2 X 1.5 mL) via SC injection on Week 28 and every 6 months (26 weeks) thereafter plus bictegravir (BIC) 75 mg tablets once daily orally at Week 28 and will continue up to Week 80. Participants willing to continue the study beyond Week 80 will continue to receive SC LEN 927 mg injection every 6 months (26 weeks) and oral daily BIC 75 mg tablets from Week 80 onwards. B/F/TAF B/F/TAF Participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) FDC tablets once daily orally from Day 1 and throughout their participation in the study up to Week 80
- Primary Outcome Measures
Name Time Method Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 54 as Determined by the United States Food and Drug Administration (US FDA)-Defined Snapshot Algorithm Week 54 The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 54 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 54 window was between Day 323 and 413 (inclusive). Percentages were rounded off.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 28 as Determined by the US FDA-defined Snapshot Algorithm Week 28 The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 28 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 28 window was between Days 176 and 231 (inclusive). Percentages were rounded off.
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 38 as Determined by the US FDA-defined Snapshot Algorithm Week 38 The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 38 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. Week 38 window was between Days 232 and 322 (inclusive). Percentages were rounded off.
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 80 as Determined by the US FDA-defined Snapshot Algorithm Week 80 The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 80 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. The Week 80 window was between Days 505 and 595 (inclusive). Percentages were rounded off.
Change From Baseline in Log10 HIV-1 RNA at Week 28 Baseline, Week 28 Change From Baseline in Log10 HIV-1 RNA at Week 38 Baseline, Week 38 Change From Baseline in Log10 HIV-1 RNA at Week 54 Baseline, Week 54 Change From Baseline in Log10 HIV-1 RNA at Week 80 Baseline, Week 80 Change From Baseline in Clusters of Differentiation 4+ (CD4+) Cell Count at Week 28 Baseline, Week 28 Change From Baseline in CD4+ Cell Count at Week 38 Baseline, Week 38 Change From Baseline in CD4+ Cell Count at Week 54 Baseline, Week 54 Change From Baseline in CD4+ Cell Count at Week 80 Baseline, Week 80 Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) Up to 174.9 weeks TEAEs were defined as 1 or both of any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. Percentages were rounded off.
Percentage of Participants Who Experienced Maximum Postbaseline Laboratory Abnormalities Up to 174.9 weeks Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline visit, up to last exposure date for participants who permanently discontinued study drug. Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: life-threatening. Percentages were rounded off.
Pharmacokinetics (PK) of LEN: Plasma LEN Pre-dose Concentrations for SC LEN Day 2, 8, Day 1 SC (Day 15), Week 28 and Week 54 PK of LEN : Plasma LEN Single Anytime Concentrations for the Oral LEN + DVY Day 2, 8, 15 , Week 28 and Week 54 PK of TAF (Tenofovir Alafenamide) and TFV (Tenofovir): Area Under the Concentration Versus Time Curve (AUClast) on Day 1 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1 AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2) and at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
PK of TAF and TFV (Tenofovir): Maximum Observed Concentration of Drug (Cmax) on Day 1 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1 Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
PK of TAF and TFV: Time (Observed Time Point) of Cmax (Tmax) on Day 1 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1 Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 and 2 on Day 1.
PK of TFV: Last Observed Quantifiable Concentration of the Drug (Clast) on Day 1 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose on Day 1 Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK sub study analysis was conducted for Group 1 and 2 on Day 1.
PK of TAF and TFV: AUClast at Weeks 16, 22, or 28 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TAF and TFV: Cmax at Weeks 16, 22, or 28 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TAF and TFV: Tmax at Weeks 16, 22, or 28 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TAF and TFV were summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TFV: Clast at Weeks 16, 22, or 28 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 15 participants in the treatment group receiving oral LEN (Treatment Group 3). Key PK parameters of TFV was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. For each participant, PK samples were taken at only one of the three possible visits: Weeks 16, 22, or 28. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TAF: AUClast at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
PK of TAF: Cmax at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
PK of TAF: Tmax at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). Key PK parameters of TAF was summarized for participants in the PK Sub study Analysis Set by treatment group, analyte and visit. PK substudy analysis was conducted for Group 1 at Week 38.
PK of Tenofovir Diphosphate (TFV-DP): AUClast at Weeks 4, 10, 16, or 22 0 hours (Predose) and at 1, 2, and 6 hours postdose AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A peripheral blood mononuclear cell (PBMC) substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TFV-DP: Cmax at Weeks 4, 10, 16, or 22 0 hours (Predose) and at 1, 2, and 6 hours postdose Cmax is defined as the maximum observed concentration of drug. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of TFV-DP: Tmax at Weeks 4, 10, 16, or 22 0 hours (Predose) and at 1, 2, and 6 hours postdose Tmax is defined as the time (observed time point) of Cmax. A PBMC substudy was conducted in a total of approximately 15 participants in Treatment Groups 1 and 2. For each participant, PK samples were taken at only one of the four possible visits: Weeks 4, 10, 16, or 22. A 12-hour postdose sample was collected, if possible. The PK results were combined and summarized without regard to specific study visit within the range of prespecified study visits.
PK of Bictegravir (BIC): AUClast at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
PK of BIC: Cmax at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Cmax is defined as the maximum observed concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
PK of BIC: Tmax at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Tmax is defined as the time (observed time point) of Cmax. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
PK of BIC: Clast at Week 38 0 hours (Predose) and at 0.5, 1, 2, 3, 4, 5, 6, and 8 hours postdose Clast is defined as the last observable concentration of drug. A PK substudy was conducted in at least 10 participants in each of the treatment groups receiving SC LEN (Treatment Groups 1 and 2). At Week 38, samples were analyzed for BIC only in Treatment Group 2.
Trial Locations
- Locations (53)
Howard Brown Health Center
🇺🇸Chicago, Illinois, United States
Northstar Healthcare
🇺🇸Chicago, Illinois, United States
Case Clinical Research Site/University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
AHF-The Kinder Medical Group
🇺🇸Miami, Florida, United States
Indiana University Infectious Diseases Research
🇺🇸Indianapolis, Indiana, United States
The Crofoot Research Center, Inc.
🇺🇸Houston, Texas, United States
Valleywise Community Health Center - McDowell
🇺🇸Phoenix, Arizona, United States
Pueblo Family Physicians
🇺🇸Phoenix, Arizona, United States
Ruane Clinical Research Group Inc
🇺🇸Los Angeles, California, United States
Mills Clinical Research at Men's Health Foundation
🇺🇸Los Angeles, California, United States
Eisenhower Health Center at Rimrock
🇺🇸Palm Springs, California, United States
Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Midland Florida Clinical Research Center, LLC
🇺🇸DeLand, Florida, United States
Midway Immunology and Research Center
🇺🇸Fort Pierce, Florida, United States
Washington Health Institute
🇺🇸Washington, District of Columbia, United States
August University Medical Center
🇺🇸Augusta, Georgia, United States
Mercer University, Department of Internal Medicine
🇺🇸Macon, Georgia, United States
Allegheny Health Network
🇺🇸Pittsburgh, Pennsylvania, United States
University of Cincinnati
🇺🇸Cincinnati, Ohio, United States
Prism Health North Texas
🇺🇸Dallas, Texas, United States
Peter Shalit, M.D.
🇺🇸Seattle, Washington, United States
DCOL Center for Clinical Research
🇺🇸Longview, Texas, United States
Texas Centers for Infectious Disease Associates
🇺🇸Fort Worth, Texas, United States
Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID)
🇺🇸Annandale, Virginia, United States
Denver Public Health
🇺🇸Denver, Colorado, United States
Chatham County Health Department
🇺🇸Savannah, Georgia, United States
Infectious Disease Specialists of Atlanta
🇺🇸Decatur, Georgia, United States
Rosedale Infectious Diseases
🇺🇸Huntersville, North Carolina, United States
Be Well Medical Center
🇺🇸Berkley, Michigan, United States
AHF-Midtown
🇺🇸New York, New York, United States
St. Jude Children's Research Hospital
🇺🇸Memphis, Tennessee, United States
St Hope Foundation
🇺🇸Bellaire, Texas, United States
The Ohio State University Medical Center
🇺🇸Columbus, Ohio, United States
Instituto Dominicano de Estudios Virológicos (IDEV)
🇩🇴Santo Domingo, Dominican Republic
HOPE Clinical Research
🇵🇷San Juan, Puerto Rico
Whitman-Walker Institute, Inc.
🇺🇸Washington, District of Columbia, United States
Triple O Research Institute, P.A.
🇺🇸West Palm Beach, Florida, United States
Atlanta ID Group, PC
🇺🇸Atlanta, Georgia, United States
MultiCare Rockwood HIV Critical Care Clinic
🇺🇸Spokane, Washington, United States
Floridian Clinical Research
🇺🇸Hialeah, Florida, United States
North Texas Infectious Diseases Consultants, P.A.
🇺🇸Dallas, Texas, United States
AIDS Healthcare Foundation - South Beach
🇺🇸Miami Beach, Florida, United States
St. John Newland Medical Associates
🇺🇸Southfield, Michigan, United States
East Carolina University, The Brody School of Medicine
🇺🇸Greenville, North Carolina, United States
Clinical Research Puerto Rico
🇵🇷San Juan, Puerto Rico
Proyecto ACTU, School of Medicine, University of Puerto Rico
🇵🇷San Juan, Puerto Rico
University of Colorado, Denver, University of Colorado Hospital
🇺🇸Aurora, Colorado, United States
Yale University; School of Medicine
🇺🇸New Haven, Connecticut, United States
Orlando Immunology Center
🇺🇸Orlando, Florida, United States
St. Joseph's Hospital Comprehensive Research Institute
🇺🇸Tampa, Florida, United States
KC CARE Health Center
🇺🇸Kansas City, Missouri, United States
Central Texas Clinical Research
🇺🇸Austin, Texas, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States